bioRxiv · 10.1101/2021.11.19.469258
Patient induced pluripotent stem cell-derived hepatostellate organoids establish a basis for liver pathologies in telomeropathies
Abstract
Patients with dyskeratosis congenita (DC) and related telomeropathies resulting from premature telomere dysfunction suffer from multi-organ failure. In the liver, DC patients present with nodular hyperplasia, steatosis, inflammation, and cirrhosis. We model DC liver pathologies using isogenic human induced pluripotent stem (iPS) cells harboring a causal DC mutation in DKC1, or a clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9-corrected control allele. Differentiation of these iPS cells into hepatocytes or hepatic stellate cells followed by generation of genotype-admixed hepatostellate organoids revealed a dominant phenotype in the parenchyma, with DC hepatocytes eliciting a pathogenic hyperplastic response in stellate cells independent of stellate cell genotype. Pathogenic phenotypes could be rescued via suppression of AKT activity, a central regulator of MYC-driven hyperplasia downstream of DKC1 mutation. Thus, isogenic iPS-derived admixed hepatostellate organoids offer insight into the liver pathologies in telomeropathies and provide a framework for evaluating emerging therapies.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Choi, Y., Kim, M. S., Rhoades, J. H., Johnson, N. M., Berry, C. T., Root, S., Chen, Q., Tian, Y., Fernandez, R. J., Cramer, Z., Adams-Tzivelekidis, S., Li, N., Johnson, F. B., Lengner, C. J.. 2021-11-20. Patient induced pluripotent stem cell-derived hepatostellate organoids establish a basis for liver pathologies in telomeropathies. https://doi.org/10.1101/2021.11.19.469258
Cite the original work for its findings. Save a collection to share your selection of sources.